ReCode Therapeutics is a startup developing novel treatments for genetic lung diseases like cystic fibrosis and primary ciliary dyskinesia. ReCode Therapeutics was formed by combining two companies, Transcriptx and ReCode Therapeutics, that were developing the mRNA and lipid nanoparticle technology respectively. The combined entity, ReCode Therapeutics, has a more expanded focus on genetic diseases with initial focus on lung with future applications in kidney and CNS. The company is led by David Lockhart, who spend more than 10 years at a public biotech, Amicus Therapeutics, that focuses on rare diseases. The company was founded based on the research of professors Daniel Siegwart and Philip Thomas at the University of Texas Southwestern Medical Center, and Professor Emeritus Arthur Johnson from Texas A&M University.